GovWire

Librela Solution for Injection for Dogs – SPC change

Veterinary Medicines Directorate

December 10
13:46 2024

class="gem-c-govspeak govuk-govspeak gem-c-govspeak--direction-ltr govuk-!-margin-bottom-0">

Following monitoring of pharmacovigilance data, the Summary of Product Characteristics (SPCs) for the following have been updated:

  • Librela 5mg Solution for Injection for Dogs
  • Librela 10mg Solution for Injection for Dogs
  • Librela 15mg Solution for Injection for Dogs
  • Librela 20mg Solution for Injection for Dogs
  • Librela 30mg Solution for Injection for Dogs

Section 4.6 now additionally states that in rare cases diarrhoea, emesis, ataxia, urinary incontinence, anorexia and lethargy have been reported. In very rare cases, seizure has been reported after administration of the veterinary medicinal product.

Any veterinary medicinal product which is authorised for marketing in the United Kingdom will have its Summary of Product Characteristics (SPC) available on our Product Information Database.

No medicine is 100% risk free, the SPC includes information on what adverse events have been known to occur following administration of a particular product, these can be found in either section Adverse events (3.6) or Adverse reactions (4.6).

All updates to SPCs other than template changes, are published in the medicine updates section of

Related Articles

Comments

  1. We don't have any comments for this article yet. Why not join in and start a discussion.

Write a Comment

Your name:
Your email:
Comments:

Post my comment

Recent Comments

Follow Us on Twitter

Share This


Enjoyed this? Why not share it with others if you've found it useful by using one of the tools below: